Cargando…

Real-Life Comparison of Fosfomycin to Nitrofurantoin for the Treatment of Uncomplicated Lower Urinary Tract Infection in Women

In this study, we compared the failure rates of fosfomycin and nitrofurantoin for uncomplicated urinary tract infections. We used Meuhedet Health Services’ large database to collect data on all female patients, older than 18 years, who were prescribed either antibiotic during 2013–2018. Treatment fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Shafrir, Asher, Oster, Yonatan, Shauly-Aharonov, Michal, Strahilevitz, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136215/
https://www.ncbi.nlm.nih.gov/pubmed/37189635
http://dx.doi.org/10.3390/biomedicines11041019
_version_ 1785032163113041920
author Shafrir, Asher
Oster, Yonatan
Shauly-Aharonov, Michal
Strahilevitz, Jacob
author_facet Shafrir, Asher
Oster, Yonatan
Shauly-Aharonov, Michal
Strahilevitz, Jacob
author_sort Shafrir, Asher
collection PubMed
description In this study, we compared the failure rates of fosfomycin and nitrofurantoin for uncomplicated urinary tract infections. We used Meuhedet Health Services’ large database to collect data on all female patients, older than 18 years, who were prescribed either antibiotic during 2013–2018. Treatment failure was a composite endpoint of hospitalization, emergency-room visit, IV antibiotic treatment, or prescription of a different antibiotic, within seven days of the initial prescription. Reinfection was considered when one of these endpoints appeared 8–30 days following the initial prescription. We found 33,759 eligible patients. Treatment failure was more common in the fosfomycin group than the nitrofurantoin group (8.16% vs. 6.87%, p-value < 0.0001). However, reinfection rates were higher among patients who received nitrofurantoin (9.21% vs. 7.76%, p-value < 0.001). Among patients younger than 40 years, patients treated with nitrofurantoin had more reinfections (8.68% vs. 7.47%, p value = 0.024). Treatment failure rates were mildly higher in patients treated with fosfomycin, despite having less reinfections. We suggest that this effect is related to a shorter duration of treatment (one vs. five days) and encourage clinicians to be more patient before declaring fosfomycin failure and prescribing another antibiotic.
format Online
Article
Text
id pubmed-10136215
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101362152023-04-28 Real-Life Comparison of Fosfomycin to Nitrofurantoin for the Treatment of Uncomplicated Lower Urinary Tract Infection in Women Shafrir, Asher Oster, Yonatan Shauly-Aharonov, Michal Strahilevitz, Jacob Biomedicines Article In this study, we compared the failure rates of fosfomycin and nitrofurantoin for uncomplicated urinary tract infections. We used Meuhedet Health Services’ large database to collect data on all female patients, older than 18 years, who were prescribed either antibiotic during 2013–2018. Treatment failure was a composite endpoint of hospitalization, emergency-room visit, IV antibiotic treatment, or prescription of a different antibiotic, within seven days of the initial prescription. Reinfection was considered when one of these endpoints appeared 8–30 days following the initial prescription. We found 33,759 eligible patients. Treatment failure was more common in the fosfomycin group than the nitrofurantoin group (8.16% vs. 6.87%, p-value < 0.0001). However, reinfection rates were higher among patients who received nitrofurantoin (9.21% vs. 7.76%, p-value < 0.001). Among patients younger than 40 years, patients treated with nitrofurantoin had more reinfections (8.68% vs. 7.47%, p value = 0.024). Treatment failure rates were mildly higher in patients treated with fosfomycin, despite having less reinfections. We suggest that this effect is related to a shorter duration of treatment (one vs. five days) and encourage clinicians to be more patient before declaring fosfomycin failure and prescribing another antibiotic. MDPI 2023-03-27 /pmc/articles/PMC10136215/ /pubmed/37189635 http://dx.doi.org/10.3390/biomedicines11041019 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shafrir, Asher
Oster, Yonatan
Shauly-Aharonov, Michal
Strahilevitz, Jacob
Real-Life Comparison of Fosfomycin to Nitrofurantoin for the Treatment of Uncomplicated Lower Urinary Tract Infection in Women
title Real-Life Comparison of Fosfomycin to Nitrofurantoin for the Treatment of Uncomplicated Lower Urinary Tract Infection in Women
title_full Real-Life Comparison of Fosfomycin to Nitrofurantoin for the Treatment of Uncomplicated Lower Urinary Tract Infection in Women
title_fullStr Real-Life Comparison of Fosfomycin to Nitrofurantoin for the Treatment of Uncomplicated Lower Urinary Tract Infection in Women
title_full_unstemmed Real-Life Comparison of Fosfomycin to Nitrofurantoin for the Treatment of Uncomplicated Lower Urinary Tract Infection in Women
title_short Real-Life Comparison of Fosfomycin to Nitrofurantoin for the Treatment of Uncomplicated Lower Urinary Tract Infection in Women
title_sort real-life comparison of fosfomycin to nitrofurantoin for the treatment of uncomplicated lower urinary tract infection in women
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136215/
https://www.ncbi.nlm.nih.gov/pubmed/37189635
http://dx.doi.org/10.3390/biomedicines11041019
work_keys_str_mv AT shafrirasher reallifecomparisonoffosfomycintonitrofurantoinforthetreatmentofuncomplicatedlowerurinarytractinfectioninwomen
AT osteryonatan reallifecomparisonoffosfomycintonitrofurantoinforthetreatmentofuncomplicatedlowerurinarytractinfectioninwomen
AT shaulyaharonovmichal reallifecomparisonoffosfomycintonitrofurantoinforthetreatmentofuncomplicatedlowerurinarytractinfectioninwomen
AT strahilevitzjacob reallifecomparisonoffosfomycintonitrofurantoinforthetreatmentofuncomplicatedlowerurinarytractinfectioninwomen